1. Home
  2. OMCL vs NBTX Comparison

OMCL vs NBTX Comparison

Compare OMCL & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omnicell Inc. ($0.001 par value)

OMCL

Omnicell Inc. ($0.001 par value)

HOLD

Current Price

$37.13

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$39.44

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMCL
NBTX
Founded
1992
2003
Country
United States
France
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2000
2018

Fundamental Metrics

Financial Performance
Metric
OMCL
NBTX
Price
$37.13
$39.44
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$55.83
$36.00
AVG Volume (30 Days)
803.4K
114.6K
Earning Date
04-28-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.77
N/A
Revenue
$787,309,000.00
N/A
Revenue This Year
$6.77
$58.17
Revenue Next Year
$5.22
N/A
P/E Ratio
$47.87
N/A
Revenue Growth
9.93
N/A
52 Week Low
$29.06
$7.87
52 Week High
$51.84
$57.14

Technical Indicators

Market Signals
Indicator
OMCL
NBTX
Relative Strength Index (RSI) 40.35 53.00
Support Level $35.57 $38.89
Resistance Level $44.52 $41.99
Average True Range (ATR) 1.71 2.00
MACD -0.28 -0.08
Stochastic Oscillator 23.70 73.17

Price Performance

Historical Comparison
OMCL
NBTX

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: